Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033511 · ClinicalTrials.gov registry record · Phase 3
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
A Phase 3 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 3
- Development phase
- 748
- Enrollment target
NCT03033511: Clinical Trial Phase 3 study, sponsored by AbbVie.
NCT03033511 is a Phase 3 study that was terminated before completion, run by AbbVie. The registered enrollment target is 748 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033511, a Phase 3 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 748 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Primary Outcome
OS is defined as the number of months from randomization to death of any cause. Calculated using the Kaplan-Meier methodology.
Interventions
- DRUG Dexamethasone
- DRUG Rovalpituzumab tesirine
- DRUG Placebo for dexamethasone
- DRUG Placebo for rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 748 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2019-11-20 |
| Phase | Phase 3 |
Why NCT03033511 stopped before completion
NCT03033511 is an interventional study that assigns participants to a tested intervention. The registered 748 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03033511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03033511 about?
NCT03033511 is a clinical study titled "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)". This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
What is the current status of trial NCT03033511?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 748 participants. The study started on 2017-02-07. Estimated completion is 2019-11-20.
What interventions are being tested in trial NCT03033511?
The interventions under investigation include: Dexamethasone (DRUG), Rovalpituzumab tesirine (DRUG), Placebo for dexamethasone (DRUG), Placebo for rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT03033511?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03033511's enrollment target sits among peer trials
748 472nd of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI